AbbVie Receives Health Canada Approval of ORILISSA & #226; & quot; & #162; (elagolix) for ...

Endometriosis affects up to one in 10 women of reproductive age in Canada. 7 out of 10 women being managed for endometriosis have unresolved pain throughout the month. The approval of ORILISSA is supported by data from two replicate Phase 3 studies, which evaluated nearly 1,700 women. In clinical trials, ORILISSA™demonstrated sustained relief over 12 months across the two most common types of pain: dysmenorrhea and non-menstrual pelvic pain....This story is related to the following:Pharmaceuticals
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news